T1	Participants 51 145	infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement:
T2	Participants 321 440	inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment
T3	Participants 1252 1294	ACR20 nonresponders to infliximab plus MTX
T4	Participants 1332 1348	ACR20 responders
T5	Participants 1399 1441	ACR20 nonresponders to infliximab plus MTX
T6	Participants 1496 1535	ACR20 nonresponders to MTX plus placebo
T7	Participants 2027 2081	patients who were DAS nonresponders at weeks 30 and 54
T8	Participants 2087 2152	patients without any improvement in individual clinical variables
